Type
Closure
Country
Germany
Region
Hessen; Gießen; Marburg-Biedenkopf
Location of affected unit(s)
Marburg
Sector
Manufacturing
(20 - 21) Manufacture of chemicals and pharmaceuticals
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.10 - Manufacture of basic pharmaceutical products

500 jobs
Number of planned job losses
Job loss
Announcement Date
1 July 2025
Employment effect (start)
1 July 2025
Foreseen end date
31 December 2026

Description

CSL, an Australian biopharmaceutical company, announced approximately 500 job cuts affecting its research and development (R&D) unit at its Marburg site in Hesse, Germany.

The job losses are linked to the company’s decision to gradually close its R&D activities at the site as part of a global strategic realignment, with the closure expected to be completed by the end of 2026. The positions affected are mainly permanent full-time white-collar jobs in research and development.

The exact measures for implementing the redundancies are still under discussion, with the company currently negotiating with the works council to find solutions for the affected employees. No details have been provided regarding indirect job losses, although impacts on related activities cannot be excluded. Employee representatives are involved in ongoing negotiations, while local authorities have strongly criticised the decision. The mayor of Marburg described the planned closure as a “serious blow” to the city and the wider region and indicated that support measures would be explored.

CSL operates a major site in Marburg employing around 3,000 people, making it the largest site within the group. Despite the planned closure of R&D, the company has announced plans to invest approximately €400 million in expanding its production activities at the site.


Sources

Citation

Eurofound (2025), CSL Innovation, Closure in Germany, factsheet number 204460, European Restructuring Monitor. Dublin, https://dev.eurofound.europa.eu/restructuring-events/detail/204460.